Aromatase Inhibitors Current Events | Aromatase Inhibitors News
|
| Page
1 of
17 |
325 Results |
|
|
|
Sort By:
Page Views | Date |
Aromatase inhibitors: A treatment of choice for advanced breast cancer patients
Aromatase inhibitors improve the survival of advanced breast cancer patients compared to standard hormone therapies like tamoxifen. view more (2006-09-20)
Hormone drug type makes survival difference in advanced breast cancer
Aromatase inhibitors, a type of hormone therapy used to treat advanced breast cancer in postmenopausal women, result in a small but significant increase in overall survival when compared to other hormone treatments, according to a new systematic review of studies. view more (2007-01-31)
Meta-analyses of global trials finds in favor of aromatase inhibitors
Two separate meta-analyses of clinical trials from around the world that tested tamoxifen against aromatase inhibitor drugs in postmenopausal women with early breast cancer have each reached the same conclusion: aromatase inhibitors are more effective in preventing breast cancer from coming back. view more (2008-12-12)
Breast cancer drugs may slow growth of lung cancer
A few years ago researchers discovered that, much like breast tumors, some lung tumors also thrive on estrogen. Now a medical student conducting research on a Howard Hughes Medical Institute (HHMI) fellowship and colleagues have managed to stop the growth of human lung cancer cells in mice with a class of breast cancer drugs called aromatase... view more... (2005-12-15)
13 percent of women stop taking breast cancer drug because of side effects, U-M study finds
More than 10 percent of women with breast cancer stopped taking a commonly prescribed drug because of joint and muscle pain, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center. view more (2007-09-06)
Weekly dose of osteoporosis drug prevents bone loss after breast cancer treatment
Breast cancer survivors who took a weekly dose of risedronate, sold as Actonel, lost significantly less bone than those who did not take the drug. view more (2007-09-19)
The dietary supplement genistein can undermine breast cancer treatment
Women taking aromatase inhibitors to treat breast cancer or prevent its recurrence should think twice before also taking a soy-based dietary supplement, researchers report. view more (2008-09-24)
Researchers say estrogen can kill breast cancer cells once fueled by the hormone
Fox Chase Cancer Center researchers say some breast cancer cells once fueled by estrogen can be killed by the same hormone. view more (2005-12-07)
Exemestane beats tamoxifen in first phase III head to head trial in advanced breast cancer
Hamburg, Germany: The first results from the world's only phase III trial to compare tamoxifen with the newer hormone treatment exemestane in advanced breast cancer shows that exemestane is safe, superior and lengthens progression-free survival. The median progression-free survival for patients taking exemestane was 10.9 months compared with 6.7... view more... (2004-03-16)
Progress made in understanding causes and treatment of endometriosis
Endometriosis is a poorly understood chronic disease characterized by infertility and chronic pelvic pain during intercourse. It affects between 5 to 10 million women in the U.S. view more (2009-01-20)
Penn studies point to strategies for reducing painful breast cancer drug side effects
Aromatase inhibitors, the same drugs that have buoyed long-term survival rates among breast cancer patients, also carry side effects including joint pain so severe that many patients discontinue these lifesaving medicines. view more (2009-09-29)
Study identifies causes of bone loss in breast cancer survivors
Osteoporosis is a growing concern among breast cancer survivors and their doctors, because certain cancer drugs can cause bone loss. view more (2008-11-20)
Early Promise Of Alternative Hormone Treatment For Breast Cancer
A fast-track study in this week's issue of THE LANCET suggests that the drug anastrozole could be an effective option for the treatment of postmenopausal women with hormone-sensitive early breast cancer. Tamoxifen therapy for five years after surgery is the established treatment for postmenopausal women with hormone-sensitive breast cancer.... view more... (2002-06-19)
Researchers discover new way to predict survival in older women with lung cancer
Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a novel mechanism to predict survival in older women with early stage lung cancer. The finding may have significant implications for new treatment approaches. view more (2007-11-02)
Gene duplication allowed pigs to have more babies
With increasing numbers of whole genomes being sequenced, researchers are keen to analyse the functions of the genes they contain and the proteins these genes encode. Yet, according to researchers writing in BMC Biology, to fully understand any genome, researchers must use palaeontology, geology and chemistry to help them discover the reasons why... view more... (2004-08-16)
Researchers identify key gene that may be a marker of breast cancer metastasis
Researchers at Fox Chase Cancer Center have identified an important gene involved in the spread of breast cancer that has developed resistance to long-term estrogen deprivation. view more (2007-04-19)
Letrozole following tamoxifen may benefit women with breast cancer
Switching to the drug letrozole following 5 years of treatment with tamoxifen reduces the risk of hormone-dependent breast cancer recurrence, but not overall survival, among postmenopausal women. view more (2005-09-07)
Linchpin gene may be useful target for new breast cancer therapies
University of Iowa researchers have discovered a gene that plays a linchpin role in the ability of breast cancer cells to respond to estrogen. The finding may lead to improved therapies for hormone-responsive breast cancers and may explain differences in the effectiveness of current treatments. view more (2007-09-17)
Warning of risk to breast cancer patients from vaginal oestrogen
Breast cancer specialists from one of the UK's leading cancer centres cautioned doctors (Thursday 26 January) of the risks in prescribing vaginal oestrogen to breast cancer patients being treated with the new aromatase inhibiting drugs, anastrozole, letrozole and exemestane. view more (2006-01-26)
1 in 5 early-stage breast cancer patients may not follow hormonal therapy plan
Postmenopausal women with early-stage, hormone-sensitive breast cancer have a lower risk of disease recurrence when their treatment includes a new class of hormone therapy drugs, yet one out five women prescribed the drugs may not take them regularly. view more (2006-12-18)
|
|
| Page
1 of
17 |
325 Results |
|
|
|
Sort By:
Page Views | Date |
|
